Please Wait
Applying Filters...
menu
    • menu
    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Benralizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Regeneron, AZ Regulatory Plans Bolstered By Ph. 3 Wins
    Regeneron, AZ Regulatory Plans Bolstered By Ph. 3 Wins

    07 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251106523106/en/Statistically-significant-NATRON-Phase-III-trial-results-for-hypereosinophilic-syndrome-show-FASENRA-delayed-time-to-first-flare-or-worsening-of-disease

    BUSINESSWIRE
    07 Nov 2025
    Share Share
    AstraZeneca's Asthma Drug Fails 'Smoker's Lung' Study
    AstraZeneca's Asthma Drug Fails 'Smoker's Lung' Study

    17 Sep 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/astrazenecas-asthma-drug-fails-smokers-lung-study-2025-09-17/

    REUTERS
    17 Sep 2025
    Share Share
    AstraZeneca asthma drug more effective during attack than steroids
    AstraZeneca asthma drug more effective during attack than steroids

    30 Nov 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-asthma-drug-more-effective-during-attack-than-steroids-study-finds-2024-11-27/

    REUTERS
    30 Nov 2024
    Share Share
    Fasenra approved in the EU for eosinophilic granulomatosis (EGPA)
    Fasenra approved in the EU for eosinophilic granulomatosis (EGPA)

    29 Oct 2024

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2024/fasenra-approved-in-the-eu-for-eosinophilic-granulomatosis-with-polyangiitis.html

    PRESS RELEASE
    29 Oct 2024
    Share Share
    AstraZeneca's Fasenra Approved in the US for Rare Blood Vessel Disease
    AstraZeneca's Fasenra Approved in the US for Rare Blood Vessel Disease

    19 Sep 2024

    // CONTRACTPHARMA

    https://www.contractpharma.com//contents/view_breaking-news/2024-09-18/astrazenecas-fasenra-approved-in-the-us-for-rare-blood-vessel-disease/?widget=listSection

    CONTRACTPHARMA
    19 Sep 2024
    Share Share
    AstraZeneca`s Biologic Fasenra (Benralizumab) Receives Approvals In U.S
    AstraZeneca`s Biologic Fasenra (Benralizumab) Receives Approvals In U.S

    17 Sep 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761070

    FDA
    17 Sep 2024
    Share Share